Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spine Firms Make Last-Ditch Appeals For CMS Support Of Percutaneous Lumbar Decompression

This article was originally published in The Gray Sheet

Executive Summary

Two medical device makers that stand to lose under CMS’ proposed noncoverage of percutaneous image-guided lumbar decompression say the agency’s proposal would unwisely eliminate a promising alternative to invasive surgery for the treatment of lumbar spinal stenosis. One suggests coverage with evidence development to allow more data collection, an approach also advocated by the North American Spine Society.

You may also be interested in...



Spine Firms Laud CMS’ Decision To Cover Percutaneous Lumbar Decompression In Trials

Spinal device makers, who objected to CMS’ proposal for outright noncoverage of percutaneous image-guided lumbar decompression, are pleased with the agency’s final decision to cover PILD when provided in a clinical study through coverage with evidence development.

Reimbursement Briefs: CMS Restricts Coverage For PILD Spine Surgery; OIG News

Medicare will only cover percutaneous image-guided lumbar decompression as part of qualifying clinical trials under a final national coverage determination. OIG scrutinizes Medicare Administrative Contractor performance and local coverage determination inconsistencies. More reimbursement briefs.

Final Coverage-With-Evidence-Development Guidance Delayed By CMS Staff Cuts

The CMS coverage and analysis group has had to divert its attention from finishing a CED guidance to finalizing proposed changes to the process for awarding Medicare coverage for IDE trials, primarily due to staff cuts, says Louis Jacques, who heads the group.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel